J9326
HCPCSTelisotuzumab vedotin-tllv
Official HCPCS Level II long descriptor
Injection, telisotuzumab vedotin-tllv, 1 mg
HCPCS Level II code J9326 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Telisotuzumab vedotin-tllv
Added to HCPCS: 2026-01-01
Nearby codes in J9
- J9318Inj romidepsin non-lyo 0.1mg
- J9319Inj romidepsin lyophil 0.1mg
- J9320Streptozocin injection
- J9321Inj epcoritamab-bysp 0.16 mg
- J9322Inj pemetrexed (bluepoint)
- J9323Inj pemetrexed ditromethamin
- J9324Inj, pemrydi rtu, 10 mg
- J9325Inj talimogene laherparepvec
- J9328Temozolomide injection
- J9329Inj, tislelizumab-jsgr
- J9330Temsirolimus injection
- J9331Inj sirolimus prot part 1 mg
- J9332Inj efgartigimod 2mg
- J9333Inj rozanolixizum-noli 1 mg
- J9334Inj efgart-alfa 2mg hya-qvfc
- J9341Inj thiotepa (tepylute) 1 mg
Where this code sits
Krasyn AI Coder
Get code suggestions automatically as you type notes. Free for 50 analyses.
Install for Chrome — freeSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.